⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 13, 2015Journal of Clinical Oncology

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Share

Abstract

Heterologous prime/boost with Cy/GVAX and CRS-207 extended survival for patients with pancreatic cancer, with minimal toxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Le et al. (2015) studied this question.

synapsesocial.com/papers/69de917e40ea06567955830b https://doi.org/10.1200/jco.2014.57.4244

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerOriginal Research · 2012 · 12,882 citations
2Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate CancerRCT · 2010 · 983 citations
3Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer2010 · 5,592 citations
4Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineOriginal Research · 2013 · 6,850 citations
5Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic EfficacyHuman Clinical Trial · 2010 · 251 citations